Quarterly Report
Brisbane, Oct 31, 2018 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th September 2018. The Company's cash position at the end of the quarter stood at $7.1m.
During the reporting period, Anatara received income of USD 500k, which was the remainder of the upfront payment from Zoetis Inc, that was paid upon execution of the exclusive licensing agreement for the worldwide development, manufacture, distribution and marketing of Detach, signed in May 2018. Expenditure during the quarter was in line with forecast.
Post the quarter, on the 23rd October, Anatara announced the appointment of a new Product Development Advisory Board comprising prominent independent experts in human gastrointestinal health. The group will assist the company in the development of its human health products.
Also post the quarter, on the 29th October, Anatara announced that it had received approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA) for its animal health product, Detach with the approved label, "To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets".
The Company remains sufficiently funded to execute on the development and partnering of our Gastrointestinal ReProgramming (GaRP) dietary supplement, designed to address the primary underlying factors associated with gastrointestinal disorders such as Irritable Bowel Syndrome and Inflammatory Bowel Disease.
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
